Due: December 14, 2023 Advanced System for Protection and Integrated Reduction of Encumbrances (ASPIRE) Hood-Mask Interface (HMI) program will incorporate upgrades into the current ground masks to optimize the interface between the Uniform Integrated Protective Read More
Due: January 26, 2024 Twenty-first century air mobility requires 21st century technology. Submit to the Challenge and pitch your next-generation communications, computing, and operations technology to an expert review panel of military, industry, and investment Read More
Due: December 11, 2023 Waterless Solutions for Decontamination – DTRA-JSTO is interested in furthering the manufacturing readiness level (MRL) of a waterless decontaminant developed under their research portfolio. The goal is to allow warfighters to Read More
DUE: November 5, 2026 Furthering the science of personal health informatics by providing meaningful and actionable insights to individuals through innovative personal health data collection, integration, analysis, and personalized risk assessments and interpretation.
DUE: February 23, 2024 Funding opportunity supporting impactful, large marine debris removal projects that will improve the resilience of the coastal and marine environment and implement strategies to prevent the re-accumulation of marine debris.
DUE: September 7, 2026 The National Cancer Institute invites applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research.
DUE: August 31, 2028 Funding opportunity to develop strategies and interventions to improve diagnostic safety in the heterogenous ambulatory care environment.
DUE: September 7, 2026 Seeking applications for identification of small molecules that function to elucidate the biology of disease as chemical probes or function as agonists or antagonists of disease target(s) for therapy or immunotherapy.
DUE: January 7, 2027 Funding available to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk
DUE: February 7, 2024 Funding available to provide a proof-of-principle for a novel strategy for Alzheimer Disease and Alzheimer Related Dementias (AD/ADRD) immunotherapies.